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Genetic Sex Conditions and Redefining Sex
9 December 2013
Jayce O’Shields
Introduction
Western culture has a tendency to value binaries and discreet categories that
separate its social structure and provide a sense of order and organization. The value
placed on binaries and categories may be advantageous in some aspects, but when it starts
to infringe upon the legal and medical rights of individuals not easily placed in either
binary category, it can become less advantageous.
A baby is usually classified as either male or female shortly after birth, and all future
legal, social, and economic actions and rights of that individual are more or less decided
according to this classification. A problem with this system arises when children are born
that do not neatly fit into either classification. These intersex individuals may be treated as
abnormal in many spheres of their lives, which may have detrimental effects on their
psyches. In the past, children determined to have ambiguous genitalia, defined as not fitting
into either sexual classification, have often undergone infantile surgery in order to correct
the ambiguity. In many ways, this surgical correction has had a major influence on the
social and legal futures of these individuals, since a significant portion of Western culture
depends on maintaining a sexual binary. One could say Western society may need to be
more widely educated regarding the occurrence of medical conditions that may result in
ambiguous genitalia and how to effectively integrate effected individuals into legal and
social systems.
Because medical professionals are classifying the sex of each individual that is born
and are faced with how to best treat intersex conditions in the context of a patient’s
physical, psychological, and legal needs, the medical community may need to consider
adopting a strategic guide for effectively treating intersex individuals. The first section of
this paper presents a few of the predominant genetic conditions that affect sexual
development compared to typical sexual development. The second section aims to discuss
how individuals with these conditions are typically approached in a clinical environment
and discuss potential improvements in treatments. The final section examines a few
societies in which intersex individuals are effectively integrated into the legal and social
spheres and how they may serve as examples for how Western society might improve its
treatment and classification of intersex individuals.

I.
Typical sexual development follows a specific pathway involving multiple genes,
hormones, and organs over a considerable length of time. The presence and expression of
certain genes only determine whether ovaries or testes will develop. The rest of sexual
differentiation depends upon the characteristic secretions of the gonads that develop.

Undifferentiated urogenital ridges are present in both male and female embryos
until the seventh week of gestation. At the seventh week, the sexual-determining region of
the Y chromosome (SRY) is expressed in those individuals with a Y-chromosome, and they
will eventually develop into males.1 The absence of the SRY gene leads to ovarian
development and will eventually result in a female phenotype. Before gonads begin to
develop, a double genital duct system consisting of Wolffian and Müllerian ducts as well as
a common external orifice exist in all embryos. As gonads develop, the single-duct system
will differentiate and develop while the other degenerates.
As testes develop, they begin to secrete the steroid hormone testosterone, which is
manufactured in the Leydig cells, and a peptide hormone called MIS (Müllerian-inhibiting
substance), which is manufactured in the Sertoli cells.1 The expression of the gene that
encodes MIS is induced by an SRY-associated protein and thereby accompanies testicular
development directly.1 Testosterone secreted from the testes induces the differentiation of
the Wolffian ducts into the vas deferens, epididymis, ejaculatory duct, and seminal vesicles.
In combination with dihydrotestosterone (DHT), a derivative of testosterone formed by the
enzyme 5-alpha-reductase, testosterone induces the fusion of the labioscrotal fold to form
the scrotum.1 It also stimulates the enlargement of the genital tubercle to form the penile
glans tissue. The urogenital fold develops into the urethral groove and external anal
sphincter, and the embryological cloaca develops into the bladder, urinary ducts,
bulbourethral glands, and prostate.1
In females, neither MIS nor testosterone is typically produced because no Y
chromosome accompanied by an SRY gene is present. Therefore, Müllerian ducts
differentiate into the Fallopian tubes and uterus without an ovarian hormone signal, and
the Wolffian ducts degenerate in the absence of testosterone and MIS.1 In typical female
development, the genital tubercle develops into the clitoris, and the urogenital fold
develops into the labia minora/vestibule and anal sphincter. The labioscrotal fold develops
into the labia majora, and the embryological cloaca develops into bladder, urinary ducts,
and vagina.1
Pseudovaginal Perineoscrotal Hypospadias (PPSH), XX and XY sex reversal,
Androgen Insensitivity Syndrome (AIS), and Congenital Adrenal Hyperplasia (CAH) are just
a few frequently encountered genetic conditions in which the typical process of sexual
development is altered, producing an atypical phenotype.
Pseudovaginal Perineoscrotal Hypospadias (PPSH), previously referred to as male
pseudohermaphroditism, refers to a condition involving a genital configuration in which
the urethral opening is located in the perineoscrotal region potentially accompanied by an
incompletely closed genital opening resembling a small, shallow vagina. PPSH arises from
a 5-alpha reductase enzyme deficiency. This enzyme converts testosterone to DHT in the
testes of typical males, and therefore a deficiency in males can lead to the development of
external genitalia resembling that of a typical female. The karyotypes of individuals with
PPSH are typically 46, XY.2 The SRY gene is usually present, which would typically lead to
testicular differentiation and development. However, mutations in the SRD5A2 gene on the
short arm of the second chromosome or the SRD5A1 gene on the fifth chromosome cause a
translational error in manufacturing one form of the 5-alpha-reductase enzyme.2 The
mutations typically found in the SRD5A2 gene are multiple base deletions or missense
mutations at positions 197 or 212.3

The external genitalia of individual with PPSH are often ambiguous at birth, and the
phenotype could include perineoscrotal hypospadias and a blind pseudovaginal pouch
mentioned before.2 Individuals with 5-alpha-reductase deficiency are typically reared as
females if a blind pseudovaginal pouch is present, and additional symptoms are usually not
evident until the body undergoes alterations associated with puberty. At puberty,
masculinization including typical male habitus, muscular development, voice change,
phallic enlargement, and semen production can occur due to the formation of a small
amount of DHT. Individuals may also have a small prostate and develop a scanty beard.
Amenorrhea and a lack of breast development at puberty may also be signs of this
condition.2
Biochemically, 5-alpha-reductase converts testosterone to DHT, reducing its steric
strain, or the strain caused by the repulsion of electrons that are too close together.
Molecules tend to assume the configuration where all electrons are equally spaced and
flatter, and decreased steric strain allows DHT to bind to its receptors more easily.4
Because the 5-alpha-reductase enzyme is defective, appropriate DHT transformation to a
configuration with less steric strain is greatly inhibited. Testosterone and estrogen levels as
well as testicular histology in individuals with PPSH usually resemble readings expected of
typical males. This suggests that testosterone is converted into other substances to prevent
negative feedback from inducing overproduction of testosterone. Müllerian structures are
usually absent in these individuals, and Wolffian structures can be completely
differentiated into the epididymis, ejaculatory ducts, and seminal vesicles.5 Viscous and
concentrated semen resulting from a small prostate and seminal vesicles, as well as
micropenis, may be present.5
Two forms of 5-alpha-reductase deficiency have been suggested by the work of
Leshin et al. (1978).6 One form is postulated to be the result of the aforementioned
structural alteration of 5-alpha-reductase as evidenced by an abnormal dissociation
constant for its substrate . The second form is paradoxically characterized by undetectable
5-alpha reductase activity in biopsy specimens but a normal dissociation constant for its
substrate, testosterone.6 5-alpha-DHT levels in these individuals are low, but 5-alpha-DHT
is present in basal amounts, so some masculinization occurs.7
Individuals with 5-alpha-reductase deficiency typically choose to adopt a male
gender identity at puberty, probably because the effects of testosterone in the brain can
override sociocultural factors.6 Therefore, many of these individuals may opt to undergo
sexual reconstructive procedures. High dose androgen therapy has been effective in
enhancing virilization and therefore improving self-image and sexual performance for
individuals who self-identify with the male gender.8
Sex reversal, previously referred to as true hermaphroditism, is another condition
resulting in atypical sexual development. It can occur in karyotypic males or females. A
diagnosis of complete sex reversal is rare, but it is based on the presence of a portion of the
SRY gene at Yp11.31 and the presence of some degree of both ovarian and testicular tissue.
In 46, XX individuals, sex reversal can arise from a translocation of a part of the Y
chromosome containing the SRY gene onto an X chromosome.9 Phenotypically, XX
individuals may resemble a typical male, but because only the SRY gene is present, not
accompanied by the gene encoding the H-Y antigen, 46, XX individuals still exhibit many
phenotypic characteristics that resemble a typical female.9 There are no Müllerian
structures, but bilateral scrotal or maldescended ovotestes that produce both ova and

spermatozoa are usually present.10 Individuals with genetic sex reversal are usually
infertile. Clinical comparisons to individuals with Kleinfelter’s Syndrome patients revealed
that 46, XX individuals with genetic sex reversal were also significantly smaller in stature.11
Short stature is common even though IGF1 and IGFBP2 levels are usually normal.12
Nonrandom X-chromosome inactivation ratios are common in the gonads of 46, XX
males as the SRY gene translocated from the little arm of the Y chromosome to the little
arm of an X chromosome may ensure the transcription of that chromosome by encouraging
the hypomethylation of its 5’-flanking region.13 In one case, however, reciprocal
translocation of the SRY gene on the little arm of the Y-chromosome to the big arm of the Xchromosome may have resulted in the loss of X telomeric sequences and the subsequent
differential inactivation of the X chromosome with the SRY gene.14
In 46, XY individuals, genetic sex reversal can arise from either point mutations or
deletions of the SRY gene.15 Phenotypically, individuals exhibit a phenotype mostly
resembling that of typical females as normal uteri, fallopian tubes, and external genitalia
are usually present, but many atypical secondary sex characteristics such as bilateral streak
gonads that are misshapen and histologically homogenous are usually present
accompanied by amenorrhea.16
Because genes on the X-chromosome as well as chromosomes 5, 9, 10, 12, and 17
have been shown to affect 46, XY sex reversal, the condition may exist in X-linked or
autosomal recessive forms.17 If mutations in any of these genes cause complete gonadal
dysgenesis, defined as a loss of gonadal germ line cells, the resulting condition is classified
as Swyer’s syndrome. Those with the Sporadic Testicular Agenesis (STAS) form of Swyer’s
syndrome do not have the H-Y antigen that is produced from the expression of the H-Y
gene typically found on the Y chromosome. Those with the Familial Testicular Agenesis
(FTAS) form do not have the H-Y antigen but exhibit an X-linked recessive inheritance.
Those with Familial Testicular Dysgenesis (FTDS) have the H-Y antigen but exhibit streak
gonads and a phenotype resembling that of a typical female.17
A hypoestrogenized vagina and cervix are common in XX inviduals. These
individuals are usually tall, and they may have an enlarged clitoris and a high incidence of
neoplasia in the streak gonads.18 There may be evidence that X and Y loci collaborate in
determining the typical male phenotype in XY individuals, and there may be a gene on the X
chromosome that blocks the function of the H-Y antigen and consequently inhibits typical
male phenotypic development in these individuals.19
Androgen Insensitivity Syndrome (AIS) is another condition resulting in atypical
sexual development. As its name suggests, AIS is the result of a decreased ability of
androgens to bind to their receptors and induce their typical cellular response, and because
androgens are in their greatest amounts in genotypic males, symptoms are most severe in
genotypic males. Androgen insensitivity usually occurs because testosterone cannot
effectively bind to the androgen receptors. This may be due to an abnormality in the DHT
receptor, an inefficiency of the receptor-DHAT complex, a decreased affinity of testosterone
for the receptor, or a decreased amount of receptors present.20 Phenotypic variability in
the effected population occurs because of a mutation in the AR gene on the long arm of the
X chromosome that codes for the androgen receptor.21 Point mutations and deletions
associated with neighboring genes are common, but evidence for inversions that cause a
break in the AR gene has also been found.22

The SRY gene induces testicular development and subsequent MIS and testosterone
secretion when it is present. MIS causes the Müllerian ducts to degenerate, but because the
Wolffian ducts and external structures cannot detect the androgens secreted by the testes,
the signal needed to induce differentiation, the Wolffian ducts degenerate as well, and the
external structures develop to resemble those of a typical female. Inguinal testes are
usually the result. The typical neonatal testosterone surge is dampened because the
hypothalamic-pituitary axis (HPA) cannot respond to testosterone, and positive feedback
to drastically increase testosterone levels cannot be stimulated.23 Insulin-like growth
factors (IGF) are involved in mediating testosterone action and the growth of genital tissue,
and IGFs are probably synthesized in genital tissue in response to a testosterone-induced
signal cascade. Since testosterone cannot bind and initiate the typical signal to induce IGF
synthesis, IGF1 levels are usually low in these individuals, resulting in a subsequent
decreased bone mass density (BMD).24 Gynecomastia, a blind vagina, absent uterus, and
female adnexa are common, but most cases are presented when amenorrhea becomes
evident or an inguinal hernia is presumed and determined to be inguinal testes.
Because there can be a variability in receptor dysfunction, there are a few different
types of androgen insensitivity. Partial AIS, in which androgen receptors are only slightly
insensitive to testosterone, can result in hypospadias, gynecomastia, and micropenis as
expected of general AIS. However, variability in external genitalia phenotype is exhibited as
higher concentrations of testosterone may saturate slightly insensitive androgen receptors
and induce cellular responses similar to typical responses.25 Incomplete AIS, in which
androgen receptors are not completely desensitized to androgens but do not have the
capacity to induce typical cellular responses to an adequate degree, can result in clitoral
enlargement, virilization, the dorsal fusion of the labioscrotal folds, some spermatogenesis,
and only partial androgen responsiveness. Because of these signs, the incomplete form may
be mistaken as PPSH, but androgen sensitivity tests can be used to confirm AIS.26 Testes
are usually removed soon after an AIS diagnosis because of a high risk of cancer associated
with inguinal testes.
Chymerism in heterozygous 46, XX females and linkage to other X chromosome
genes suggest AIS exhibits a simple X-linked inheritance pattern.28 The protein typically
produced from the transcription and translation of the AR gene activates the expression of
other genes. This ability depends on the structure of the N-terminal domain encoded in
exon 1 of the gene, which contains polymorphic CAG repeats. A smaller number of repeats
corresponds with a heightened ability of the AR protein to activate other genes involved in
cell growth and metabolism, possibly resulting in a higher risk of prostate cancer.27
Topical androgen gel therapy exhibits a potential to be successful in treating
individuals with partial or incomplete AIS that self-identify as male. However, according to
a study of 14 women, clinical patients have a tendency to express complete satisfaction
with their rearing, gender assignment, sexual function, and psychosexual development
based on their answers to a questionnaire and a psychosexual analysis and do not seek
gender reassignment surgery.29
In contrast to AIS, which results from the decreased ability of tissue to detect the
presence of androgens and thereby respond to them, Congenital Adrenal Hyperplasia
(CAH) is characterized by the overproduction of androgens, and therefore the hypermasculinization of body tissues. CAH is the result of a problem defect in the cortisol
synthesis pathway, most commonly the result of a mutation in the CYP21A2 gene on the

short arm of chromosome six that encodes the 21-hydroxylase enzyme.30 This condition is
therefore inherited according to an autosomal recessive pattern. A mutation in the
CYP21A2 gene causes an abnormal translation of the enzyme 21-hydroxylase, a
misconfiguration of the enzyme, and a subsequent deficiency in enzymatic activity. The
enzyme cannot convert 17-OHP to 11-deoxycortisol in the cortisol synthesis pathway and
therefore halts cortisol production.30 A decrease in cortisol production results in decreased
negative feedback to the HPA, resulting in increased adrenocorticotropic hormone (ACTH)
secretion from the adenohypophysis. Increased ACTH overstimulates the adrenal cortex
where cortisol is made in an attempt to increase cortisol production. As a result, because
androgens are also produced in the adrenal cortex, androgen production increases, leading
to masculinized external genitalia, postnatal clitoral enlargement, and early epiphyseal
closure. Hyperpigmentation can also result from the hypersecretion of
proopiomelanocortin (POMC) that accompanies the hypersecretion of ACTH and stimulates
melanocytes.31 The gonads and internal genitalia of these individuals usually resemble
those of typical males. Salt wasting can result because the disruption of the cortisol
synthesis pathway at the 21-hydroxylase reaction also causes a decrease in aldosterone
secretion from the adrenal cortex, a huge decrease in salt reabsorption in the kidneys and
sweat glands, and therefore large amounts of salt excreted.32
Because CAH can result from a disruption of any enzyme in the cortisol synthesis
pathway, there are multiple types of CAH. The two main classifications are classic and nonclassic. The classic type is further divided into the salt-wasting form and the simple
virilizing form. Because classic CAH can result in massive salt loss, the classic type is
usually more severe while the symptoms of the non-classic type are usually only found late
in life and are therefore less sever. In XX individuals, the classic form produces a phenotype
that includes clitoromegaly and the fusion of the urethra and vaginal canal, therefore it is
usually diagnosed at birth. XY individuals are more commonly diagnosed with the salt
wasting form of classic CAH than XX individuals. XY individuals with the simple virilizing
form of CAH display early virilization, potentially including an enlarged penis and body
hair, between the ages of 2 and 4. Individuals with the non-classic form of CAH exhibit
similar virilization to the classic type including infertility, oligomenorrhea, amenorrhea,
polycystic ovarian syndrome, and acne in XX individuals, but symptoms occur later in
adolescence. Sometimes symptoms never appear and the diagnosis is not made until the
individual is tested for another condition from which atypical test results provide evidence
for CAH. Individuals with CAH may also be behaviorally masculinized, so there is a high
incidence of homosexuality in females.33
Phenotypic variation is very broad in individuals with CAH because problems
leading to CAH can arise during splicing, because the expression of 21-hydroxylase can be
altered by genes in the renin-angiotensin systems, and because variable temporal and
spatial gene expression occurs.34, 35 Bilateral testicular masses have been observed in XY
individuals as well as clitoromegaly, gynecomastia, and labial fusion in XX individuals. Late
sexual maturation, decreased incidence of pregnancies, and early onset osteoporosis
because of decreased BMD are also common in XX individuals. Adrenal stimulation by
ACTH can cause adrenal hypertrophy (increased adrenal area), tumors, and adrenal
atrophy from exhaustive stimulation.36 Amygdala function may also be impaired by the
hypersecretion of CRH in both XX and XY individuals leading to decreased emotional and
fear responses.37 Low thyrotropin-stimulating hormone (TSH) has been observed because

increased hypothalamic/pituitary/adrenal activity decreases TSH secretion, which also
leads to decreased adrenomedullary function via epinephrine and norepinephrine.38
Decreased levels of thyroxine from decreased TSH secretion leads to a decrease in the
permissive action of thyroxine on epinephrine and can also disrupt glycemic control.39
Testicular tumors or the impairment of Leydig cells as a result of decreased plasma
testosterone can lead to decreased spermatogenesis, subsequent azoospermia, and poor
semen quality in affected XY males as well.40
A fourth cryptic form of CAH is characterized by typical 21-hydroxylase deficiency
that is accompanied by no symptoms with the exception of an increased incidence of
tumors.
Amniotic fluid steroid analysis is only successful in diagnosing the salt-wasting form
of CAH, but a first day urine analysis of 17-hydroxyprogesterone and androstenedione can
provide an accurate diagnosis of all forms.41,42 Nighttime low dosage dexamethasone
therapy can dissipate adrenal masses and restore fertility. It is recommended during
pregnancy because it crosses the placenta quickly, has a long half-life, and has a large
suppressive effect on ACTH, although it may affect verbal working memory and selfperception.43 The non-classic form of CAH may be treated by adrenocorticosteroids
potentially accompanied by adrenalectomy.44
Non-classic CAH is the most frequent autosomal recessive genetic condition with an
overall frequency of 1 in 5,000 births, although frequencies in Zurich are even higher and
gene frequencies in Ashkenazi Jewish populations can reach 0.223.45 In contrast to the
severe symptoms that can occur as a result of CAH, there is a heterozygote advantage for
carriers due to the fact that cortisol levels are higher and therefore stress response is
heightened and the individuals is therefore more efficient in coping with physiological
stress.46

II.
Many conditions like the ones described in Part I are diagnosed as Disorders of
Sexual Development (DSD), a general category that includes all conditions that result in
atypical sexual development. The treatment of these conditions can be very extensive,
sometimes including hormone replacement, multiple surgeries, and a great number of
medications. Historically, the sexual development of an individual along one of the two
typical pathways is emphasized in medical professions, and therefore medical
professionals are accustomed to treating patients classified as either male or female.
Therefore, when a child is born with ambiguous genitalia or any number of other DSDs,
many medical professionals may not be completely confident in how to treat these
individuals. The pressure of potentially altering the physical, social, and psychological traits
of these individuals combined with a low level of social and medical exposure to
individuals with these conditions may make it difficult for medical professionals to know
how to effectively treat them. Because the social structure of modern Western society
includes such a distinct gender and sexual binary, doctors and other medical professionals
are often unable to separate their concern with the social implications of intersex
individuals and the medical consequences of certain DSDs for the individuals themselves.

Most of these complications stem from a previously perceived necessity for immediate
medical or surgical intervention when an individual with a DSD is presented as well as the
customary practice of determining sex from only two options.
Some DSDs impose large health risks on the effected individuals and should be
treated in a way that minimizes these risks and detrimental effects. For example, because
CAH involves cortisol and aldosterone deficiencies and subsequent salt wasting,
hypotension, dehydration, hyponatremia, hyperkalemia, and even death, immediate action
to minimize these issues is medically necessary.47 Gonadal dysgenesis and hypospadias
often accompanying DSDs result in higher frequencies of gonadoblastomas and urinary
tract infections, which again should be treated to prevent detrimental health effects.48 But
many other DSDs have little to no detrimental side effects. Patients with Androgen
Insensitivity Syndrome (AIS) have a theoretical risk for gonadoblastomas, but this risk can
be drastically reduced by simply removing the gonads in one surgical procedure.49 The
effects of any treatment beyond what is medically necessary should be carefully
considered.
The treatment of many DSDs have been historically linked to social placement and
gender socialization because intersex individuals often do not fit into male/female binary
categories so relied upon in traditional Western medical practice. Before the late 1970s,
there was a minimal focus on how to treat intersex patients effectively considering what
was in the best interest of the patient. For example, infantile clitoroplasty in individuals
with clitoromegaly has been very common to conform ambiguous genitalia to the shape,
size, and configuration seen in typical females. This procedure was generally used in any
case of genital abnormality, usually defined as a morphology that made it difficult to
identify the presence of an adequate penis. Used in an effort to ensure the classification of
these babies as female, these surgical procedures can potentially reduce the individuals’
genital sensations, which can be detrimental to their sexual pleasure, overall sexual
satisfaction, self-image, and sexual performance, which can then lead to even more
negative effects psychologically.
Any child born that had an atypical karyotype was considered a social and medical
emergency. Following any infantile genital reconstruction surgeries, parents of the
individual were advised to keep the nature of the condition confidential, and all intersex
children were recommended to be reared as females as reductive surgery is quicker, easier,
and cheaper than surgeries that required the addition of tissue.50 In addition to
unnecessary infantile sexual reconstructive surgeries, past studies used to determine the
severity of CAH were even illogically based on which gender-charged toys affected children
played with rather than on biochemical or physical symptoms.33
In the late 1970s, however, Dr. Milton Edgerton at Johns Hopkins University and the
University of Virginia started producing a bulk of scientific literature recommending
proper clinical treatment of intersex and transsexual individuals, including the
psychological and surgical facets of their treatments. He started to separate the social and
medical aspects of individuals with DSDs and transgendered individuals. His goal was to
make the medical aspects of treatment more objective and to construct a comprehensive
list of standard guidelines for treating these conditions in an attempt to make the
treatment of these individuals more fulfilling for the patients themselves in regards to their
clinical health and psychological satisfaction. Before long, “gender dysphoria” became an
official diagnosis for intersex or transgendered individuals who felt that their gender

socialization did not correspond with the sex they felt they inhabited. Edgerton began
calling reconstructive surgeries “sex-confirmation operations” rather than sexualreassignment operations. Advocacy groups of medical professionals and social advocates
began to construct and modify the guidelines on how to treat these individuals in a clinical
setting. Eventually, necessary reconstructive surgery needed to improve healthy body
function such as the cosmetic correction of hypospadias, previously conducted to appease a
social binary, was separated from the type of reconstructive surgery desired by the patient
utilized to re-enter society as a member of their self-identified sex. Similarly, the use of
infantile clitoroplasty and other unnecessary procedures to alter ambiguous genitalia were
restricted.51
A shift to patient centered medicine involving transgendered patients or patients
with DSDs altered the way these individuals were treated. Steps were taken to ensure that
gender dysphoria was authentic by a “gender team” of medical professionals across many
fields. Professional thoroughly presented patients with the risks involved in “sex
confirmation operations” and were required to be declared physically and mentally fit for
gender reassignment by a group of psychologists and surgeons before the process could be
initiated. Preliminary real-life tests were conducted, requiring a patient to publicly and
privately assume the role of the opposite gender to ensure adequate transitioning following
irreversible surgery.51 Aesthetically satisfying cosmetic alterations were considered to be
important, but proper functioning and sensation of surgically altered genitalia were
considered very high priorities. Gender reassignment surgeries for transgendered men
who identified as women aimed to produce a neovagina capable of intercourse and a
sensate clitoris capable of inducing orgasms in order to maximize sexual satisfaction.52
Genetic counseling services were also made available to inform the patient of their
condition, and counseling was framed around being sensitive to the patient and explaining
that their condition, although atypical, is normal and something that happened before they
were born at no fault of their parents or themselves.53
Many legal battles then began to arise over how men and women who have
undergone “sex-confirmation surgeries” should be categorized legally and who is legally
responsible for children with DSDs. In 1999, the Constitutional Court of Columbia stated
that children born with ambiguous genitalia were treated based on the wishes of their
parents granted the parents were concerned for the wellbeing of the child, not
themselves.50 Although a step in the right direction, a more considerate model for
treatment was developed later. Milton Diamond and Keith Sigmundson developed an
extensive list of guidelines that should be strictly followed when treating individuals with
DSDs and/or infants that may mature to be transgendered. This list included a full and
concise genital inspection at birth, a primary focus on major health risks such as electrolyte
imbalances and hypospadias associated with CAH, and patience during the meticulous
inspection. This model included full disclosure of information to the parents and an
encouragement to seek counseling while being reminded the condition arose due to fault of
no one. A focus on the affected patient was paramount in this model, and while sex might
be classified due to the likelihood of how that individual would develop psychologically and
physiologically, no major operations would be performed to solidify the classification. Once
the patient is able to make informed decisions about his or her condition, then physical
changes can be made provided they are eligible according to the aforementioned criteria.
Diamond and Sigmundson’s model was built on communication and positive messages, an

approach finely tuned to both the psychological and medically aspects of treatment. And
their main point was that most intersex conditions do not necessitate major surgery for the
patient to feel socially and psychologically fulfilled.54 This model is still widely used today,
and has been modified to appeal to individuals in relation to their contexts. A book called
Transgender Emergence also provides a very comprehensive guideline for an integrated
treatment involving many sociocultural techniques to be used by health professionals and
social workers to improve the quality of treatment for the patients.55
Presently, there are still many legal battles happening involving insurance coverage
of sexual reassignment surgeries and other treatments regarding DSDs and transgendered
identity. Twenty-eight states do not have explicit Medicaid regulations about coverage, 21
states have explicit regulations excluding coverage, and those that do not have explicitly
exclusive regulations do explicitly exclude cosmetic or experimental procedures.56 Of
course, common legal arguments in favor of including “sex-confirmation surgeries” rest on
the fact that reassignment surgery has been proven to be effective and fulfilling for the
patient and that if denied surgery, a person’s psychological health may be negatively
impacted.
Knowledge and awareness about how to treat DSDs and how to improve the
psychological health of transgendered individuals should be emphasized in medical
communities. Many individuals with AIS and other DSDs have had less than quality medical
evaluations and have undergone marginalization by their healthcare professionals and
therefore less than effective treatments.49 Sometimes, the biggest issue is how to cope with
the social and psychological implications of DSDs, for example when doctors must decide
how to manage masculinization at puberty of individuals with 5-Alpha Reductase
Deficiency. Patient-centered care that involves a multidisciplinary approach by medical
and other support teams well versed in how to convey sensitivity toward these individuals
is of the utmost importance.48 Because some intersex and transgendered individuals are
undergoing changes that could potentially be traumatic, more follow up studies need to be
conducted on how patients respond under these guidelines of care. Individuals need to
supply informed consent on how they would like to be treated, which means some families
may need to wait 10-15 years after their child is born with a DSD to make decisions about
how to approach the condition medically if intervention is an option.50
Groups like the World Professional Association for Transgender Health (WPATH)
constantly construct and revise the Standards of Care of intersex individuals. The
Endocrine Society has created guidelines on how to properly diagnose DSDs and how to
confer treatment. The Gay and Lesbian Medical Association (GLMA) aims to create a
welcoming community of medical professionals prepared to treat DSDs and transgendered
individuals, and Accord Alliance is an advocacy group for legal and social change
surrounding the rights of transgendered individuals. Websites like YouthResource and
Trans Basics are also immensely concerned with these individuals’ experiences in the
doctor’s office.57 These groups and many like them are making great strides toward
informing medical professionals and families of patients with DSDs on how to manage
these conditions medically and socially. A larger emphasis on integrating these methods
into medical school curriculums as a part of sensitivity and ethical training has also been
widely advocated.
Developing uniform standard guidelines for how to treat transgendered individuals
and individuals with DSDs is becoming easier as the people developing them continue to

consider the comfort and well being of the patient, but we must also be careful in realizing
that within the diagnosis of gender dysphoria or any of the many DSDs, individuals can
vary widely with regard to medical needs and psychological states of mind. Not every
individual can be treated the same way and yield optimal results. Just as in other fields,
each patient must be treated as an individual, and these guidelines may need to be
modified depending on the particular patient’s needs. These challenges still comprise a
large gray area of medicine that needs to be constantly modified and fine-tuned.58
The language used in the medical field regarding DSDs and intersex individuals also
needs to be altered. Lee et al. (1996) proposed that a DSD should be redefined as a
“congenital condition in which development of chromosomal, gonadal, or anatomic sex is
atypical,” which emphasizes that DSDs are not abnormal or disorderly, simply atypical. The
renaming of true hermaphroditism, male pseudohermaphroditism, and testicular
feminization as sex reversal, PPSH, and AIS are also steps in the right direction as they
reflect the physiological and clinical aspects of the condition rather than traditional social
responses to these atypical phenotypes. The connotation that words carry in a diagnosis
can have a great impact on how the effected individual views himself or herself when the
condition is not under his or her control, so medical jargon is worth considering in
reference to these conditions in order to conform to the guidelines set forth by Midgerton,
Diamond and Sigmundson, and countless other organizations.

III.
Although Western society typically has a tough time integrating individuals into
society who do not fit into the widely accepted male-female binary, many societies around
the world have found it relatively easy and simple to effectively incorporate these
individuals into society by reorganizing society rather than by reclassifying these
individuals. Intersex or transgendered individuals are even greatly admired or considered
divine in some societies.
A significant percentage of the Dominican Republic population are effected by 5alpha reductase deficiency or PPSH described in Part I. These individuals are called the
guevedoces, and as implied by the Spanish term roughly translated to “testicles at 12,” these
individuals are born with ambiguous genitalia and raised as female until puberty, at which
time they start to exhibit male secondary sexual characteristics including the descendance
of testicles and penile growth. The guevedoces exhibit a typical male karyotype, but because
of a lack or deformation of the 5-alpha reductase enzyme, these individuals are unable to
convert testosterone to DHT.59 This form of 5-alpha reductase deficiency or PPSH has been
classified as Type 2 Familial Incomplete Male Pseudohermaphroditism while Type 1 has
been understood to be Reifenstein syndrome.60 PPSH is similar to Reifenstein syndrome
but is characterized by autosomal inheritance and gynecomastia. It is characterized
biochemically by a structural alteration of 5-alpha-reductase exhibited by an abnormal
dissociation constant (Km) and low levels of enzymatic activity.6
In the 1970s, Dr. Julianne Imperato-McGinley visited a small mountain village in the
Dominican Republic to study the guevedoces and found that they composed about 2% of the
general population.5 In Dominican society, she found that these individuals were legally

and socially considered as a third sex. As their phenotypic transformations progress, the
guevedoces assume a male gender role in society and usually identify as a heterosexual
male with a common desire to father children despite being reared as females for over a
decade. This major shift in gender association completely contradicted Money’s theory that
gender identity becomes fixed at three years old by insinuating that gender identity can
completely reverse at least until puberty.61 Dr. Imperato-McGinley’s findings also suggest
that gender identity is partly biological and partly sociological. Therefore, she wonders if
these individuals assume a male identity at puberty because they are pressured to by
society or if they are biologically prone to undergo a shift in gender identity due to
physiological and psychological changes.
Regardless of the exact origin and cause of this gender shift, the classification of this
subpopulation as a third sex in Dominican society provides a model for how sex and gender
should be classified in Western culture. By recognizing the guevedoces as members of a
separate sex, the people of the Dominican Republic recognize that a strict sexual
dimorphism is not universal in humans.62 The sexual transformation of these individuals is
welcomed by joyous celebrations and although these individuals may encounter slight
stigmas as a statistical minority, they are at least acknowledged as a third group. They
aren’t expected to fit into the strict sexual binary imposed by Western culture because they
recognize that a strict sexual binary is inapplicable in nature, including the human species.
The recognition of these individuals has not only had social implications, but
medical ones as well. Once the physiological effects of 5-alpha reductase deficiency were
identified and studied, pharmacological treatments for benign prostate hyperplasia were
developed. The discovery of the trophic effects on the prostate by DHT led to the
development of 5-alpha reductase inhibitors like finasteride and dutasteride were in order
to treat prostate hyperplasia by replicating the physiological effects that 5-alpha reductase
deficiency has on the prostate of the guevedoces.63
The Dominican Republic is not the only country or society that embraces intersex
and transgendered individuals as a normal part of society. Native-American “two-spirits”
who identify with both their feminine and masculine spirits are considered divine in many
North American tribes. The hijra of India and south Asia are sometimes holy people and
carry out many sacred rituals. They are even included in many holy texts as divinities. The
nation of Bangladesh has officially recognized their classification as a third sex. A kathoey of
Thailand is a transgendered, homosexual, or intersex individual that is regarded as a
product of karma and is widely recognized as a master within the entertainment and
fashion businesses. The list of societies who recognize and embrace the presence of
intersex or transgendered individuals is not exhausted here, and they serve as beautiful
examples for Western society, proving societies that recognize and integrate transgendered
or intersex individuals as integral parts of society often flourish.

Conclusion
Although it is often the genesis of social injustice towards intersex and
transgendered individuals, the sexual dichotomy that is engrained in Western culture is not
completely based on illusion. Sexual dimorphisms are very prevalent in nature and used to

classify the members of the species. Body structures can be vastly different in males and
females of different species. For example, the neuronal cluster of the hypothalamus is
markedly larger in males than in females of humans.64 The purpose of this paper, however,
is not to refute that strict sexual dimorphisms and dichotomies exist, but that in the wide
variation of life, they should not be considered the only possibilities. And in a human
context in which society is a major aspect of life, the sex of an individual that does not
clearly fall into either category should not be the cause of being socially ostracized or
labeled as abnormal. This philosophy can be extended to the variety of sexualities that exist
in the human population as well. Evidence for linkage of human male homosexuality to a
gene on the long arm of the X chromosome has been presented as well as a genetic
mutation in fruit flies that causes homosexual male courtship behaviors.65,66 And it is
widely accepted among scientists that a huge variety of sexualities is exhibited in the rest of
the animal kingdom. Physiology is a result of a very large number of molecules interacting
together in complex ways determined by the genetic code in each living thing. This complex
interaction of molecules is the machine that manufactures the variety of life. And every
molecule in every pathway provides an opportunity for change that should be considered
natural and normal. Everything we are as a member of the animal kingdom is determined,
in some part, by our biology, and our social abilities should not seek to override this fact
but to embrace it.
This paper has illustrated that there are many genetic and physiological origins of
intersex conditions. Intersex and transgendered individuals, although statistically atypical,
are not abnormal but naturally occurring individuals like any other individual that is
considered typical. Medical standards acknowledging the rights of these individuals are
transforming, and they should continue to be adjusted as more knowledge and experience
is gained concerning how to effectively treat these individuals. Because sexual classification
has dramatic effects on social integration, legal standing, a sense of sexuality, self-identity,
and the overall sense of well being of an individual, these medical standards cannot be
completely objective but must be continuously adjusted for each individual in the context
of each individual’s life. The acknowledgement and respectful incorporation of these
treatments into the medical field can initiate a shift in social stigmas surrounding these
individuals and progress toward establishing a society in which all human beings are
treated with respect. So many cultures around the world have adopted policies of equality
and justice for these individuals in social, medical, legal, and religious spheres, and it is
time for Western society to follow in these footsteps. Every human being on earth has a
certain amount of androgens and estrogens inside them, and the ratios of the two and the
effects they have on the morphology of the body should not be considered a social
emergency, but a social opportunity for progress and equality.
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